UC Irvine Links Dopamine Loss to Alzheimer's Memory Decline, Parkinson's Drug Restores Memory in Mice

A New Mechanism for Memory Loss

Scientists at the University of California, Irvine have identified a surprising new driver of Alzheimer's memory decline: a breakdown of the dopamine system in the entorhinal cortex, a brain region that acts as a gateway to the hippocampus and memory formation. The study, published in Nature Neuroscience, found that dopamine levels in this region fell to less than one-fifth of normal in Alzheimer's mouse models, leaving neurons unable to encode new experiences.

The research was led by Kei Igarashi, a Chancellor's Fellow and associate professor of anatomy and neurobiology at the UC Irvine School of Medicine, together with collaborators from the RIKEN Center for Brain Science in Japan. The team built on earlier work showing dopamine is essential for learning in the entorhinal cortex, and discovered that in Alzheimer's model mice, that system simply stops responding to signals that should trigger memory formation.

Repurposing a Parkinson's Drug

Using optogenetic techniques to boost dopamine in the affected region, researchers restored the animals' ability to form new memories. They then showed that Levodopa, a drug already approved and widely prescribed for Parkinson's disease, produced strikingly similar results, normalising neural activity and reversing memory deficits.

Because Levodopa is already FDA-approved, has a well-understood safety profile, and is cheap to manufacture, the findings could dramatically accelerate clinical investigation in people with early-stage Alzheimer's disease, where tens of millions of patients worldwide have few effective options.

A Shift in Treatment Strategy

The discovery represents a notable departure from the dominant Alzheimer's research agenda, which has focused on clearing toxic proteins such as amyloid-beta and tau tangles. Those approaches have produced only modest clinical benefits and have struggled to restore memory once damage takes hold. By targeting the brain's dopamine circuitry instead, the UC Irvine team offers a complementary angle, addressing how memory circuits malfunction rather than just what accumulates in them.

The work was funded by the National Institutes of Health, the Alzheimer's Association, and the BrightFocus Foundation, and adds to a growing wave of research, including recent findings on brain immune cells, tau-targeting drugs, and patient-derived brain organoids, that is rapidly broadening the scientific understanding of Alzheimer's disease.